Transgenic transchromosomal rodents for making human antibodies

US10076103B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10076103-B2
Application numberUS-201615218202-A
CountryUS
Kind codeB2
Filing dateJul 25, 2016
Priority dateNov 30, 2000
Publication dateSep 18, 2018
Grant dateSep 18, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.

First claim

Opening claim text (preview).

What is claimed is: 1. An isolated nucleic acid encoding the heavy and light chain variable region sequences isolated and amplified from cDNA generated from mRNA, wherein the mRNA is isolated and amplified from B lymphocytes comprising rearranged immunoglobulin sequences, wherein the rearranged immunoglobulin sequences are produced by a method comprising: providing a transgenic mouse that comprises two human immunoglobulin loci, wherein one human immunoglobulin locus is a human heavy chain locus located on an autonomous transchromosome comprising a fragment of human chromosome 14 having a human chromosome 14 centromere, and the other human immunoglobulin locus is a human light chain locus transgene integrated into the mouse genome, and obtaining the rearranged immunoglobulin sequences from the transgenic mouse. 2. An isolated nucleic acid encoding the heavy chain variable region sequence isolated and amplified from cDNA generated from mRNA, wherein the mRNA is isolated and amplified from B lymphocytes comprising rearranged immunoglobulin sequences, wherein the rearranged immunoglobulin sequences are produced by a method comprising: providing a transgenic mouse that comprises two human immunoglobulin loci, wherein one human immunoglobulin locus is a human heavy chain locus located on an autonomous transchromosome comprising a fragment of human chromosome 14 having a human chromosome 14 centromere, and the other human immunoglobulin locus is a human light chain locus transgene integrated into the mouse genome, and obtaining the rearranged immunoglobulin sequences from the transgenic mouse. 3. An isolated nucleic acid encoding the light chain variable region sequence isolated and amplified from cDNA generated from mRNA, wherein the mRNA is isolated and amplified from B lymphocytes comprising rearranged immunoglobulin sequences, wherein the rearranged immunoglobulin sequences are produced by a method comprising: providing a transgenic mouse that comprises two human immunoglobulin loci, wherein one human immunoglobulin locus is a human heavy chain locus located on an autonomous transchromosome comprising a fragment of human chromosome 14 having a human chromosome 14 centromere, and the other human immunoglobulin locus is a human light chain locus transgene integrated into the mouse genome, and obtaining the rearranged immunoglobulin sequences from the transgenic mouse. 4. A vector comprising the nucleic acid of claim 1 . 5. An expression vector comprising the nucleic acid of claim 1 in which the heavy and light chain variable regions sequences of the nucleic acid are operatively linked with a regulatory sequence that controls expression of the nucleic acid in a host cell. 6. A host cell comprising the nucleic acid of claim 1 , or progeny of the cell. 7. The host cell of claim 6 , which is a eukaryote. 8. A method of producing a human antibody display library, comprising: introducing an immunogen into a transgenic mouse, wherein the transgenic mouse comprises two human immunoglobulin loci, wherein one human immunoglobulin locus is a human heavy chain locus located on an autonomous transchromosome comprising a fragment of human chromosome 14 having a human chromosome 14 centromere, and the other human immunoglobulin locus is a human light chain locus transgene integrated into the mouse genome; isolating a population of nucleic acids encoding human antibody chains from lymphatic cells of the transgenic mouse; and forming a library of display packages displaying the antibody chains, wherein a library member comprises a nucleic acid encoding an antibody chain displayed from the package. 9. The method of claim 8 , wherein the transgenic mouse lacks a detectable titer to the immunogen when the isolating is performed. 10. The method of claim 8 , wherein the immunogen is encoded by a nucleic acid. 11. The method of claim 10 , wherein the nucleic acid encodes a membrane bound receptor.

Assignees

Inventors

Classifications

  • Knock-out vertebrates · CPC title

  • comprising antibodies · CPC title

  • against CD4 · CPC title

  • for producing genetically modified animals, e.g. transgenic · CPC title

  • Animal expressing industrially exogenous proteins · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10076103B2 cover?
The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
Who is the assignee on this patent?
Kyowa Hakko Kirin Co Ltd, Squibb & Sons Llc, Squibb & Sons Llc
What technology area does this patent fall under?
Primary CPC classification A01K67/0278. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).